Kåre I. Birkeland

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

John Dormandy, B Charbonnel, D.J.A. Eckland et al. · The Lancet · 2005 · 4.1K citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +15

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed et al. · The Lancet · 2018 · 1.8K citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity

K. Malmberg, Lars Rydén, Hans Wedel et al. · European Heart Journal · 2005 · 1.1K citations · Full text

Medicine, Cardiology, Internal Medicine +16

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs

Mikhail Kosiborod, Matthew A. Cavender, Alex Z. Fu et al. · Circulation · 2017 · 814 citations · Full text

Medicine, Cardiology, Pharmacology +16

Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2

John Willy Haukeland, Jan Kristian Damås, Zbigniew Konopski et al. · Journal of Hepatology · 2006 · 601 citations

Veterinary Medicine, Immunology, Pathology +14